Top in hem/onc: Aspirin use in breast cancer survivors, CAR-T for non-Hodgkin lymphoma

In vitro and in vivo evidence has suggested that aspirin may have an antitumor effect, and several studies revealed longer survival in patients with breast cancer who used aspirin regularly compared with nonusers, according to researchers.

However, new results from the Aspirin after Breast Cancer trial showed that daily aspirin use failed to reduce the risk for breast cancer recurrence. It was the top story in hematology/oncology last week.

The second top story explored the role of chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Results from a randomized phase 3 study found that one CAR-T significantly outperformed the current standard of care, according to study investigator Manali Kamdar, MD.

Read these and more top stories in hematology/oncology below:

Daily aspirin use fails to reduce risk for breast cancer recurrence

Use of aspirin failed to prolong invasive disease-free survival among patients with breast cancer, according to results of a randomized phase 3 study presented during the ASCO Plenary Series. Read more.

CAR-T poised to create ‘paradigm shift’ in non-Hodgkin lymphoma

Since the approval of the first CAR T-cell therapy, the research community has grappled with a crucial question. Is the modality appropriate for earlier use by patients with certain types of cancer? Read more.

Cardiovascular risk factors prevalent among patients with triple-negative breast cancer

Patients with triple-negative breast cancer have a high prevalence of cardiovascular risk factors that increase their risk for noncancer morbidity and mortality, according to study results. Read more.

Telemedicine fails to reduce, may widen disparities in cancer care, study shows

Patients newly diagnosed with cancer and considered to be of high socioeconomic status had the highest use of telehealth in the early days of the COVID-19 pandemic, according to a research letter published in JAMA Oncology. Read more.

Niraparib regimen ‘new first-line option’ for certain men with metastatic prostate cancer

The addition of niraparib (Zejula) to abiraterone acetate (Zytiga, Janssen) and prednisone improved outcomes for certain men with prostate cancer, according to randomized phase 3 study results presented at ASCO Genitourinary Cancers Symposium. Read more.